125 related articles for article (PubMed ID: 9641888)
21. Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: evidence for a cyclin D1-dependent cell cycle progression.
Poch B; Gansauge F; Schwarz A; Seufferlein T; Schnelldorfer T; Ramadani M; Beger HG; Gansauge S
Pancreas; 2001 Oct; 23(3):280-7. PubMed ID: 11590324
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous deregulation of p16 and cyclin D1 genes in pancreatic ductal adenocarcinoma: a combined immunohistochemistry and image analysis study based on tissue microarrays.
Tsiambas E; Karameris A; Gourgiotis S; Salemis N; Athanassiou AE; Karakitsos P; Papalois A; Merikas E; Kosmidis P; Patsouris E
J BUON; 2007; 12(2):261-7. PubMed ID: 17600882
[TBL] [Abstract][Full Text] [Related]
23. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
25. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.
Juuti A; Louhimo J; Nordling S; Ristimäki A; Haglund C
J Clin Pathol; 2006 Apr; 59(4):382-6. PubMed ID: 16467169
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma.
Ohkouchi T; Sakuragi N; Watari H; Nomura E; Todo Y; Yamada H; Fujimoto S
Am J Obstet Gynecol; 2002 Aug; 187(2):353-9. PubMed ID: 12193924
[TBL] [Abstract][Full Text] [Related]
28. [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
Tomaszewska R
Folia Med Cracov; 1999; 40(1-2):101-41. PubMed ID: 10909469
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of analysis of DNA in pancreatic adenocarcinoma by flow cytometry.
Hyöty M; Visakorpi T; Kallioniemi OP; Mattila J; Laippala P; Nordback I
Eur J Surg; 1991 Oct; 157(10):595-600. PubMed ID: 1687251
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).
Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Carrasco JC; Requena MJ; Montironi R
Eur Urol; 2004 May; 45(5):606-12. PubMed ID: 15082203
[TBL] [Abstract][Full Text] [Related]
31. Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer.
Hiroshima Y; Nakamura F; Miyamoto H; Mori R; Taniguchi K; Matsuyama R; Akiyama H; Tanaka K; Ichikawa Y; Kato S; Kobayashi N; Kubota K; Nagashima Y; Goshima Y; Endo I
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S369-78. PubMed ID: 22805864
[TBL] [Abstract][Full Text] [Related]
32. An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas.
Ohshio G; Suwa H; Imamura T; Yamaki K; Tanaka T; Hashimoto Y; Imamura M
Scand J Gastroenterol; 1998 May; 33(5):535-9. PubMed ID: 9648995
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
Jeong J; Park YN; Park JS; Yoon DS; Chi HS; Kim BR
Yonsei Med J; 2005 Aug; 46(4):519-25. PubMed ID: 16127777
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of PUMA in pancreatic ductal adenocarcinoma.
Du QH; Zhang KJ; Jiao XL; Zhao J; Zhang M; Yan BM; Xu YB
J Int Med Res; 2012; 40(6):2066-72. PubMed ID: 23321162
[TBL] [Abstract][Full Text] [Related]
35. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.
Michalides R; Hageman P; van Tinteren H; Houben L; Wientjens E; Klompmaker R; Peterse J
Br J Cancer; 1996 Mar; 73(6):728-34. PubMed ID: 8611372
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients.
Novotný J; Petruzelka L; Vedralová J; Kleibl Z; Matous B; Juda L
Neoplasma; 2001; 48(3):188-91. PubMed ID: 11583287
[TBL] [Abstract][Full Text] [Related]
37. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
38. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma.
Lu CD; Morita S; Ishibashi T; Hara H; Isozaki H; Tanigawa N
Cancer; 1999 Mar; 85(6):1250-60. PubMed ID: 10189129
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
Kallakury BV; Sheehan CE; Ambros RA; Fisher HA; Kaufman RP; Ross JS
Cancer; 1997 Aug; 80(4):753-63. PubMed ID: 9264360
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas.
Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
Hepatogastroenterology; 2001; 48(39):879-83. PubMed ID: 11462947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
